title: The attenuated nine mile phase II clone 4/RSA439 strain of Coxiella burnetii is highly virulent for severe combined immunodeficient (SCID) mice.
abstract: The Nine Mile phase II clone 4 (NMIIC4) strain of Coxiella burnetii is an attenuated phase II strain that has lost the genes for virulence determinant type 1 lipopolysaccharide. These bacteria were very virulent for severe combined immunodeficient (SCID) mice. The lethal dose 50 (LD50) was ~10 bacteria. Infected SCID mice died between Day 28 and Day 53 post-infection. At termination of the experiment (Day 60) only 5 of 24 mice had survived. The degree of splenomegaly was directly related to the bacterial load in the SCID mice spleens. The NMIIC4 was avirulent in immunocompetent wild mice and bacterial DNA copies in splenic tissue were extremely low. The SCID mice that were inoculated with high doses of heat inactivated NMIIC4 C. burnetii were all alive at Day 60 and without splenomegaly. It appears that the phase I lipopolysaccharide present in virulent Nine Mile phase I but not in attenuated NMIIC4 is not the only virulence factor for C. burnetii.
authors: Department of Microbiology, Pathology North-Hunter, NSW Health Pathology, John Hunter Hospital, Locked Bag 1, HRMC, Australia; Australian Rickettsial Reference Laboratory, Barwon Health, Geelong, Australia.
authors: Aminul
authors: A
authors: Islam
authors: Michelle
authors: M
authors: Lockhart
authors: John
authors: J
authors: Stenos
authors: Stephen
authors: S
authors: Graves
mesh_terms: D000818:Animals; D016997:Coxiella burnetii / Q000145:classification* / Q000235:genetics / Q000472:pathogenicity*; D051379:Mice; D016513:Mice, SCID; D011778:Q Fever / Q000382:microbiology*; D013154:Spleen / Q000382:microbiology; D014774:Virulence
references: Ann N Y Acad Sci. 2003 Jun;990:505-9
references: 12860682
references: Infect Immun. 2002 Dec;70(12):6726-33
references: 12438347
references: J Endotoxin Res. 2000;6(5):369-76
references: 11521057
references: Lett Appl Microbiol. 2011 May;52(5):514-20
references: 21338377
references: FEMS Immunol Med Microbiol. 2012 Feb;64(1):61-5
references: 22092959
references: Infect Immun. 2007 Dec;75(12):5845-58
references: 17893129
references: Infect Immun. 2009 Dec;77(12):5640-50
references: 19786560
references: FEMS Immunol Med Microbiol. 2004 Nov 1;42(3):291-7
references: 15477042
references: Ann N Y Acad Sci. 2003 Jun;990:510-20
references: 12860683
references: Ann N Y Acad Sci. 2005 Dec;1063:167-70
references: 16481509
references: Infect Immun. 2003 Aug;71(8):4717-23
references: 12874353
references: Infect Immun. 1985 May;48(2):359-65
references: 3988339
references: Vaccine. 1997 Nov;15(16):1779-83
references: 9364683
references: J Exp Med. 1988 Mar 1;167(3):1016-33
references: 3280724
references: J Gen Microbiol. 1986 Sep;132(9):2587-94
references: 3794655
references: Rev Infect Dis. 1983 Jul-Aug;5(4):790-800
references: 6622891
references: FEMS Microbiol Lett. 2007 Feb;267(1):102-7
references: 17156123
references: Infect Immun. 2007 Jul;75(7):3245-55
references: 17438029
references: J Immunol. 1984 Apr;132(4):1804-8
references: 6607948
references: Nature. 1983 Feb 10;301(5900):527-30
references: 6823332
references: Infect Immun. 1986 Apr;52(1):337-40
references: 3957431
references: J Biol Chem. 1987 Apr 5;262(10):4740-7
references: 3558367
references: Infect Immun. 1987 May;55(5):1144-50
references: 3570458